全部照片(1)
About This Item
經驗公式（希爾表示法）:
C16H18FN3O2
CAS號碼:
分子量：:
303.33
Beilstein:
8072099
MDL號碼:
分類程式碼代碼:
12352200
PubChem物質ID:
NACRES:
NA.77
暫時無法取得訂價和供貨情況
推薦產品
化驗
≥98% (HPLC)
形狀
powder
藥物控制
USDEA Schedule V
顏色
white to light brown
溶解度
DMSO: >15 mg/mL
儲存溫度
room temp
SMILES 字串
FC1=CC=C(CNC2=CC(N)=C(NC(OCC)=O)C=C2)C=C1
InChI
1S/C16H18FN3O2/c1-2-22-16(21)20-15-8-7-13(9-14(15)18)19-10-11-3-5-12(17)6-4-11/h3-9,19H,2,10,18H2,1H3,(H,20,21)
InChI 密鑰
PCOBBVZJEWWZFR-UHFFFAOYSA-N
基因資訊
human ... KCNQ1(3784) , KCNQ2(3785) , KCNQ3(3786) , KCNQ4(9132) , KCNQ5(56479)
尋找類似的產品？ 前往 產品比較指南
生化／生理作用
瑞替加滨是一种 Kv7.2-7.5 钾通道激活剂； 抗惊厥药。
瑞替加滨（依佐加滨）是一种具有抗惊厥活性的 Kv7.2-7.5 （KCNQ2-5）神经元钾通道开放剂。
訊號詞
Danger
危險聲明
危險分類
Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Aquatic Acute 1 - Aquatic Chronic 1
儲存類別代碼
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
水污染物質分類（WGK）
WGK 3
閃點（°F）
Not applicable
閃點（°C）
Not applicable
從最近期的版本中選擇一個：
分析證明 (COA)
Lot/Batch Number
客戶也查看了
Gökce Orhan et al.
Expert opinion on pharmacotherapy, 13(12), 1807-1816 (2012-07-13)
Epilepsy is a serious and common chronic neurological disease with an urgent need for novel treatment options, because 30% of all epilepsy patients do not respond to currently available drugs. Retigabine/Ezogabine (RTG) is a third-generation antiepileptic drug (AED) with a
Roger J Porter et al.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics, 4(1), 149-154 (2007-01-03)
Retigabine is a novel antiseizure drug that acts through potassium channels and has activity in a broad range of animal models of epilepsy. It is also effective in several preclinical pain models. The drug has been extensively studied in phase
Martin J Gunthorpe et al.
Epilepsia, 53(3), 412-424 (2012-01-10)
The pharmacologic profile of retigabine [RTG (international nonproprietary name); ezogabine, EZG (U.S. adopted name)], is different from all currently approved antiepileptic drugs (AEDs). Its primary mechanism of action (MoA) as a positive allosteric modulator of KCNQ2-5 (K(v) 7.2-7.5) ion channels
Michele A Faulkner et al.
Expert opinion on drug safety, 12(6), 847-855 (2013-07-26)
Complex-partial seizures are frequently resistant to antiepileptic therapy. Two new medications with mechanisms of action novel within the antiepileptic class have recently received approval for the adjunctive treatment of partial (focal) seizures. A Medline search was conducted to identify preclinical
Philip N Patsalos et al.
Expert opinion on pharmacotherapy, 13(5), 699-715 (2012-03-13)
The search for new, more effective antiepileptic drugs (AEDs) continues. The three most recently approved drugs, the so-called third-generation AEDs, include lacosamide, retigabine and eslicarbazepine acetate and are licensed as adjunctive treatment of partial epilepsy in adults. For the above
Active Filters
我們的科學家團隊在所有研究領域都有豐富的經驗，包括生命科學、材料科學、化學合成、色譜、分析等.
聯絡技術服務
